Literature DB >> 21816781

Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis.

Vin-Cent Wu1, Shyh-Chyi Lo, Yuh-Lien Chen, Po-Hsun Huang, Chia-Ti Tsai, Chan-Jung Liang, Chin-Chi Kuo, Yih-Shing Kuo, Bai-Chin Lee, En-Ling Wu, Yen-Hung Lin, Yun-Yu Sun, Shuei-Liong Lin, Jaw-Wen Chen, Shing-Jong Lin, Kwan-Dun Wu.   

Abstract

CONTEXT: Primary aldosteronism (PA) is associated with a higher incidence of cardiovascular events, probably through mineralocorticoid receptor (MR)-dependent endothelial cell dysfunction, in comparison with essential hypertension (EH).
OBJECTIVE: Our objective was to investigate the number and function of endothelial progenitor cells (EPC) in PA and the relationship with arterial stiffness and disease progression. DESIGN AND
SETTING: We conducted a prospective study of the change of EPC number and outcome of PA patients after treatment at a tertiary medical center. PRIMARY OUTCOMES: Changes in arterial stiffness and EPC number after treatment and the curability of hypertension were assessed. PATIENTS: A total of 113 PA patients (87 patients diagnosed with aldosterone-producing adenoma, 26 with idiopathic hyperaldosteronism) and 55 patients with EH participated.
RESULTS: PA patients had higher arterial stiffness than EH patients (P = 0.006), with a lower numbers of circulating EPC and endothelial colony-forming units (P < 0.05). The differences were ameliorated at 6 months after unilateral adrenalectomy or treatment with spironolactone. Expression of MR was identified in the EPC. The number of circulating EPC was inversely correlated with the plasma aldosterone concentration (P = 0.021), arterial stiffness (P = 0.029) and serum high-sensitivity C-reactive protein (P = 0.03). High-dose aldosterone (10(-5) and 10(-6) m) attenuated EPC proliferation and angiogenesis in vitro. Among the 45 patients who underwent unilateral adrenalectomy, 32 (71%) were cured of hypertension. The preoperative number of EPC [log(EPC number percent) >-3.6] predicted the curability of hypertension after adrenalectomy (P = 0.003).
CONCLUSIONS: The relative deficiency of EPC in PA patients may contribute to aldosterone vasculopathy, which can be reversed by adrenalectomy and spironolactone. High aldosterone levels attenuated EPC proliferation and angiogenesis. Circulating EPC number may be a valuable biomarker to identify PA patients with a high incidence of arterial stiffness and to predict postoperative residual hypertension of aldosterone-producing adenoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21816781     DOI: 10.1210/jc.2011-1135

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Primary aldosteronism in 2011: Towards a better understanding of causation and consequences.

Authors:  Michael Stowasser
Journal:  Nat Rev Endocrinol       Date:  2011-12-13       Impact factor: 43.330

2.  Hemojuvelin modulates iron stress during acute kidney injury: improved by furin inhibitor.

Authors:  Guang-Huar Young; Tao-Min Huang; Che-Hsiung Wu; Chun-Fu Lai; Chun-Cheng Hou; Kang-Yung Peng; Chan-Jung Liang; Shuei-Liong Lin; Shih-Chung Chang; Pi-Ru Tsai; Kwan-Dun Wu; Vin-Cent Wu; Wen-Je Ko
Journal:  Antioxid Redox Signal       Date:  2013-09-17       Impact factor: 8.401

3.  A Novel Somatic Mutation of CACNA1H p.V1937M in Unilateral Primary Hyperaldosteronism.

Authors:  Chi-Shin Tseng; Kang-Yung Peng; Shuo-Meng Wang; Yao-Chou Tsai; Kuo-How Huang; Wei-Chou Lin; Ya-Hui Hu; Vin-Cent Wu; Jeff S Chueh
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

4.  The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old.

Authors:  Chin-Chi Kuo; Poojitha Balakrishnan; Yenh-Chen Hsein; Vin-Cent Wu; Shih-Chieh Jeff Chueh; Yung-Ming Chen; Kwan-Dun Wu; Ming-Jiuh Wang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2014-07-16       Impact factor: 1.636

5.  Aldosterone promotes cardiac endothelial cell proliferation in vivo.

Authors:  Basile Gravez; Antoine Tarjus; Véronique Pelloux; Antoine Ouvrard-Pascaud; Claude Delcayre; Janelise Samuel; Karine Clément; Nicolette Farman; Fréderic Jaisser; Smail Messaoudi
Journal:  J Am Heart Assoc       Date:  2015-01-06       Impact factor: 5.501

6.  Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population.

Authors:  Vin-Cent Wu; Kuo-How Huang; Kang-Yung Peng; Yao-Chou Tsai; Che-Hsiung Wu; Shuo-Meng Wang; Shao-Yu Yang; Lian-Yu Lin; Chin-Chen Chang; Yen-Hung Lin; Shuei-Liong Lin; Tzong-Shinn Chu; Kwan-Dun Wu
Journal:  Sci Rep       Date:  2015-06-12       Impact factor: 4.379

7.  Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients.

Authors:  Chih-Chin Kao; Pei-Chen Wu; Che-Hsiung Wu; Li-kwang Chen; Hsi-Hsien Chen; Mai-Szu Wu; Vin-Cent Wu
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

8.  Long term outcome of Aldosteronism after target treatments.

Authors:  Vin-Cent Wu; Shuo-Meng Wang; Chia-Hui Chang; Ya-Hui Hu; Lian-Yu Lin; Yen-Hung Lin; Shih-Chieh Jeff Chueh; Likwang Chen; Kwan-Dun Wu
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

9.  Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients.

Authors:  Che-Wei Liao; Lian-Yu Lin; Chi-Sheng Hung; Yen-Tin Lin; Yi-Yao Chang; Shuo-Meng Wang; Vin-Cent Wu; Kwan-Dun Wu; Yi-Lwun Ho; Fumitoshi Satoh; Yen-Hung Lin
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

10.  Urinary π-glutathione S-transferase Predicts Advanced Acute Kidney Injury Following Cardiovascular Surgery.

Authors:  Kai-Hsiang Shu; Chih-Hsien Wang; Che-Hsiung Wu; Tao-Min Huang; Pei-Chen Wu; Chien-Heng Lai; Li-Jung Tseng; Pi-Ru Tsai; Rory Connolly; Vin-Cent Wu
Journal:  Sci Rep       Date:  2016-08-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.